BLU News and Press, BELLUS Health Inc. From 04/18/23

2023-04-18 10:04:36 ET Gainers: Dermata Therapeutics ( DRMA ) +108% . BELLUS Health ( BLU ) +99% . Allarity Therapeutics ( ALLR ) +69% . Gamida Cell ( GMDA ) +37% . YS Biopharma ( YS ) +28% . Losers: China Jo-Jo Drugs...

2023-04-18 07:16:38 ET Listen on the go! Subscribe to Wall Street Breakfast on Apple Podcasts and Spotify Bellus ( BLU ) surges ~100% after GSK ( GSK ) reaches deal to acquire cough drugmaker for ~$2B. Apple ( AAPL ) opens its first store in...

2023-04-05 13:07:31 ET Canadian biotech Bellus Health ( NASDAQ: BLU ) announced Wednesday Phase 1 data for its lead asset camlipixant (BLU-5937), highlighting results as a demonstration of its proof of concept as an extended-release (“ER”) formulation in refractory chr...

Once-daily Extended-Release formulation demonstrated equivalent bioavailability to twice-daily Immediate Release formulation Extended-Release formulation was well tolerated, with the safety profile consistent with previous camlipixant trials and no taste-related adverse events reporte...

2023-03-21 16:48:45 ET BELLUS Health press release ( NASDAQ: BLU ): FY GAAP EPS of -$0.66 beats by $0.07 . Revenue of $16M (flat Y/Y). For further details see: BELLUS Health GAAP EPS of -$0.66 beats by $0.07, revenue of $16M

- Patient enrollment ongoing in the CALM Phase 3 program with topline data expected for CALM-1 in the second half of 2024 - - Ended year with US$337.1 million in cash, cash equivalents and short-term investments; cash runway extends to the second half of 2025 and through expected ...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today...

Summary Refractory chronic cough remains as a complex condition that requires a medical breakthrough for treatment. BELLUS Health Inc. is pushing ahead on this front, with recent support from evidence in its recent clinical trials. We note several potential inflection points from cl...

BELLUS Health press release ( NASDAQ: BLU ): Q3 GAAP EPS of -$0.20 misses by $0.03 . Revenue of $4K (fat Y/Y). Ended third quarter 2022 with $364.4M in cash, cash equivalents and short-term investments; Cash runway extended to the second half of 2025 and through ex...